The Peptide NewsroomPeptide research, industry and supply-chain headlines

Centric Compounding Recalls Six Lots of Injectable Wellness Vials Over Elevated Endotoxin Levels

Photograph: Pills Medicine
Photo: "Pills Medicine" by Michal Jarmoluk is marked with CC0 1.0. Source: https://stocksnap.io/photo/pills-medicine-I4P7JN8SCN

Houston-based Centric Compounding is voluntarily recalling six lots of injectable products to the consumer level after finding elevated endotoxin levels, according to a company announcement posted by the FDA on September 9, 2026. The FDA notes that it posts these announcements as a public service and does not endorse either the product or the company.

The affected products are Glutathione 200mg/mL, Myer's Cocktail, and Tri-Immune Boost, sold in 30mL multidose vials and described in the notice as being used to support immunity, fatigue, and general wellness. All three were compounded using a glutathione active ingredient that the company says was found to contain elevated endotoxin levels.

Why endotoxins matter in an injectable

Endotoxins are bacterial cell-wall fragments that can trigger a strong immune response when they enter the bloodstream, which is why the limits on them are tightest for products given by injection rather than by mouth. The company's risk statement is unusually blunt: there is a reasonable probability that injectable products with elevated endotoxin levels could cause significant medical events including fevers, hypotension, inflammatory reactions, anaphylactic shock and death.

Nine reports already

Centric Compounding says it has received nine reports of fever, chills, chest pain, nausea and vomiting, headache, and malaise. That cluster of symptoms is consistent with what the notice describes as the endotoxin risk, and nine reports is not a theoretical signal, which is presumably why the recall reaches all the way to the consumer level rather than stopping at distributors.

Where the vials went

Distribution was nationwide, and the notice specifies two routes: home delivery directly to patients and delivery to prescribers. Home delivery is the harder half of that problem, because a vial sitting in someone's refrigerator does not get pulled off a shelf by a pharmacist.

The company says it is notifying distributors and customers by email and arranging replacement of all recalled products. Its instruction to consumers holding affected vials is to stop using and discard them, and to contact a physician or healthcare provider about any problems that may be related to the product.

What happens next

The recall is being conducted with the knowledge of the FDA, and adverse reactions or quality problems can be reported through the agency's MedWatch program. What the notice does not say is how many vials are in the six lots, or how the endotoxin contamination reached a compounded product in the first place.

Source: FDA — Recalls. Read the original.

Filed under: fda, supply

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

HHS Won't Act Against Six Unapproved Peptides, But FDA Reviewers Advised Against Listing Them

HHS says it will not act against pharmacies compounding BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon, despite FDA reviewers recommending against listing all six. The notice sets no end date, adds no test of the finished vial, and is open for public comment through November 13.

HHS Opens Compounding to BPC-157 and Five Peptides, But FDA Scientists Objected

HHS will allow state-licensed pharmacies to compound BPC-157, TB-500, epitalon, MOTS-c, KPV and semax under quality conditions, while stating the policy does not establish safety or effectiveness. FDA reviewers had found the BPC-157 studies too small and no human safety studies at all for four of the six.

FDA Sends Interim Peptide Compounding Policy to White House, But Experts Say Access Isn't Approval

The FDA has sent an interim peptide compounding policy to the White House, which could let pharmacies compound unapproved peptides including BPC-157 while permanent rules are written. Pharmacists and physicians quoted in the coverage stress that enforcement discretion is not approval and not evidence of safety.